Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

In a report released on June 8, from UBS maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target of HK$141.10. The company’s share...

RemeGen Co. Ltd. Class H (9995) Gets a Buy from UBS

RemeGen Co. Ltd. Class H ( ($HK:9995) ) just unveiled an announcement. RemeGen has secured conditional marketing approval from China’s National Med...

RemeGen Wins Conditional China Nod for Telitacicept in IgA Nephropathy

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The RAPID registry from Regeneron and Sanof...

RAPID Real‑World Dupixent Data Could Extend Regeneron and Sanofi’s Asthma Edge

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron’s CLIO-1 trial, officially titled “A Phase 1 Study...

Regeneron’s CLIO-1 Update: What a Completed Early Lymphoma Trial Means for REGN Investors

Regency Centers ( ($REG) ) just unveiled an announcement. On June 1, 2026, Regency Centers Corporation released an updated investor presentation fo...

Regency Centers Updates Investor Presentation and Outlook Materials

Regency Centers ( ($REG) ) just unveiled an update. On June 1, 2026, Regency Centers Corporation released an updated investor presentation for use ...

Regency Centers Updates Investor Presentation to Enhance Transparency

In a report released on May 28, from Morgan Stanley maintained a Hold rating on RemeGen Co. Ltd. Class H, with a price target of HK$98.00. The comp...

Morgan Stanley Keeps Their Hold Rating on RemeGen Co. Ltd. Class H (9995)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The Phase 1, open-label study titled “A Phase 1, Open-Label,...

Regeneron Steps Into CAR T for Advanced Prostate Cancer With New Phase 1 Trial

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a mid-stage trial calle...

Regeneron Expands Into Pulmonary Hypertension With New Phase 2 Trial for REGN13335

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a late-stage study call...

Regeneron Targets Stroke Prevention Gap With New Atrial Fibrillation Trial

In a report released today, Michael Lewis from Truist Financial maintained a Buy rating on Regency Centers, with a price target of $84.00. Accordin...

Truist Financial Keeps Their Buy Rating on Regency Centers (REG)

Regency Centers ( ($REG) ) has shared an update. On May 28, 2026, Regency Centers released its 2025 Corporate Responsibility Report, emphasizing th...

Regency Centers Highlights 2025 Corporate Responsibility Progress

Regency Centers ( ($REG) ) has provided an update. On May 28, 2026, Jacksonville-based Regency Centers released its 2025 Corporate Responsibility R...

Regency Centers Highlights Sustainability in 2025 Responsibility Report

The latest announcement is out from Regency Centers ( ($REG) ). On May 27, 2026, Regency Centers Corporation released an updated investor presentat...

Regency Centers Updates Investor Presentation for Shareholders

An announcement from Regency Centers ( ($REG) ) is now available. On May 27, 2026, Regency Centers Corporation released an updated investor present...

RBC Capital analyst Craig Wong-Pan upgraded Regis Healthcare Ltd. to a Buy on May 25 and set a price target of A$7.50. The company’s shares closed ...

Regis Healthcare Ltd. (REG) was upgraded to a Buy Rating at RBC Capital

The latest update is out from RemeGen Co. Ltd. Class H ( ($HK:9995) ). RemeGen Co., Ltd. has been actively deploying part of its idle self-owned fu...

RemeGen Expands Use of Idle Funds in HTSC Wealth Products

Analysts are intrested in these 5 stocks: ( ($REGN) ), ( ($CRCL) ), ( ($BURL) ), ( ($ROST) ) and ( ($PBA) ). Here is a breakdown of their recent


Regeneron, Circle, Burlington, Ross, Pembina Trending With Analysts

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Merck & Company (MRK) with bull...

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Merck & Company (MRK)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals has completed a mid-stage clinical...

Regeneron’s REGN7544 Trial Reaches Key Milestone in Sepsis-Induced Hypotension

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN) and Regeneron (REGN...

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Regeneron (REGN)

The latest update is out from Regency Centers ( ($REG) ). On May 18, 2026, Regency Centers Corporation released an updated investor presentation fo...

Regency Centers Updates Investor Presentation for Conferences

An announcement from Regency Centers ( ($REG) ) is now available. On May 18, 2026, Regency Centers Corporation released an updated investor present...

RemeGen Co. Ltd. Class H ( ($HK:9995) ) just unveiled an update. RemeGen Co., Ltd. has proposed amendments to its articles of association to reflec...

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron...

Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Tonix Pharma (TNXP) and Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Korro Bio (KRRO) with bullish s...

Analysts Are Bullish on These Healthcare Stocks: Regeneron (REGN), Korro Bio (KRRO)

Citi analyst Geoff Meacham downgraded Regeneron to a Hold yesterday and set a price target of $700.00. According to TipRanks, Meacham is a 5-star a...

Citi downgrades Regeneron (REGN) to a Hold

Last week, stocks pulled back from record highs as oil, yields, and rate fears returned to the forefront. The S&P 500 (SPX) ended at 7,408.50, down...

The Week That Was, The Week Ahead: Macro and Markets, May 17

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, called “A Prospective, Observati...

Real-World Dupixent Data in Canada: What Regeneron and Sanofi Investors Should Watch

RemeGen Co. Ltd. Class H ( ($HK:9995) ) has shared an announcement. RemeGen Co., Ltd. has approved a cash management plan allowing the use of up to...

RemeGen Deploys Idle Cash Into RMB453 Million HTSC Wealth Products

Traders seeking the top stock market stories for Tuesday will find them in our roundup.


Morning News Wrap-Up, 5/12/26: Today’s Biggest Stock Market Stories!

Smart Powerr Corp stock was up after the company said it would work to regain listing compliance.


Market Cap	$13.12B	P/E Ratio	16.40
52W High	$81.66	52W Low	$66.86
Div Yield	302.0%	Payout Ratio	123.3%
EPS Growth 3Y	0.0%	52W Position	85.7%
Overall Score	82	Value Score	100
Quality Score	68	Technical Score	80

EPS Current Est	$4.85	EPS Next Est	$5.09
EPS Growth Est	+4.9%	DPS Growth 3Y	4.3%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$79.55	+2.57%	2.57M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$79.55	+2.6%	2.57M
3
4
5
6

REG

REG

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel